Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same
View Patent ↗Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
1. An isolated human antibody, or antigen-binding portion thereof, which is capable of binding to the p40 subunit of human interleukin 12 (IL-12) and dissociates from human IL-12 with a k off rate constant of about 1×10 −4 s −1 to 1×10 −5 s −1 , as determined by surface plasmon resonance, wherein the antibody is capable of binding to a first heterodimer and is also capable of binding to a second heterodimer, wherein the first heterodimer comprises the p40 subunit of human IL-12 and the p35 subunit of human IL-12, and wherein the second heterodimer comprises the p40 subunit of human IL-12 and a p19 subunit.
2. The antibody of claim 1 , or antigen-binding portion thereof, wherein the antibody neutralizes the biological activity of the first heterodimer.
3. The antibody of claim 1 , or antigen-binding portion thereof, wherein the antibody neutralizes the biological activity of the second heterodimer.
4. The antibody of claim 1 , or antigen-binding portion thereof, wherein the antibody neutralizes the biological activity of the first heterodimer and the second heterodimer.
5. The isolated antibody of claim 1 , or antigen binding portion thereof, which dissociates from human IL-12 with a K d of 1.34×10 −10 M or less, as determined by surface plasmon resonance.
6. An isolated human antibody, or antigen-binding portion thereof, which is capable of binding to the p40 subunit of a first heterodimer comprising the p40 subunit of human IL-12 and the p35 subunit of human IL-12, and to the p40 subunit of a second heterodimer comprising the p40 subunit of human IL-12 and a p19 subunit, wherein the antibody dissociates from human IL-12 with a k off rate constant of about 1×10 −4 s −1 to 1×10 −5 s −1 as determined by surface plasmon resonance, and wherein the antibody, or antigen-binding portion thereof, neutralizes the biological activity of the first heterodimer and the second heterodimer.
7. An isolated human antibody, or antigen-binding portion thereof, which is capable of binding to the p40 subunit of a first heterodimer comprising the p40 subunit of human IL-12 and the p35 subunit of human IL-12, and to the p40 subunit of a second heterodimer comprising the p40 subunit of human IL-12 and a p19 subunit, wherein the antibody, or antigen-binding portion thereof, dissociates from human IL-12 with a K d of 1.34×10 −10 M or less or a k off rate constant of about 1×10 −4 s −1 to 1×10 −5 s −1 , as determined by surface plasmon resonance, and which neutralizes the biological activity of the first heterodimer and the second heterodimer.
8. The isolated human antibody, or antigen-binding portion thereof, of any of claims 1 , 7 or 6 , wherein the antibody comprises a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions.
9. The isolated human antibody, or antigen-binding portion thereof, of any one of claims 1 , 7 , or 6 , wherein the antibody or antigen-binding portion thereof comprises an IgG1 heavy chain constant region.
10. The isolated human antibody, or antigen-binding portion thereof, of any one of claims 1 , 7 , or 6 , wherein the antibody or antigen-binding portion thereof is a Fab fragment.
11. The isolated human antibody, or antigen-binding portion thereof, of any one of claims 1 , 7 , or 6 , wherein the antibody or antigen-binding portion thereof is a F(ab′ 2 ) fragment.
12. The isolated human antibody, or antigen-binding portion thereof, of any of claims 1 , 7 , or 6 , wherein the antibody or antigen-binding portion thereof is a single chain Fv fragment.
13. The isolated human antibody, or antigen-binding portion thereof, of any of claims 1 , 7 or 6 , wherein the antibody or antigen-binding portion thereof does not neutralize the activity of mouse IL-12.
14. The isolated antibody of any one of claims 1 , 7 or 6 , or antigen binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an in vitro phytohemagglutinin (PHA) assay with an IC 50 of 1×10 −9 M or less.
15. The isolated antibody of any of claims 1 , 7 or 6 , or antigen binding portion thereof, wherein the antibody inhibits phytohemagglutinin blast proliferation in an in vitro PHA assay with an IC 50 of 1×10 −8 M or less.
16. The isolated antibody of any of claims 1 , 7 or 6 , or antigen binding portion thereof, wherein the antibody inhibits phytohemagglutinin blast proliferation in an in vitro PHA assay with an IC 50 of 1×10 −7 M or less.
17. The isolated human antibody, or antigen binding portion thereof, of any of claims 1 , 2 - 4 , 7 or 6 , wherein the antibody inhibits human interferon γ (IFNγ) production with an IC 50 of 1.6×10 −10 M or less.
18. A pharmaceutical composition comprising the antibody or an antigen binding portion thereof, of any one of claims 1 , 2 - 4 , 5 , 7 , and 6 and a pharmaceutically acceptable carrier.